Condition: Acute Ischemic Stroke · Sponsor: Huashan Hospital
The CHESTNUT trial is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial. The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg/kg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without substantial infarction on non-contrast computed tomography (NCCT) in an extended time window.
This description comes directly from the study's public registry record.
Xin Cheng, MD, PhD · +86 021-52887145 · chengxin@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Huashan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Huashan Hospital, Fudan University | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06994975